Skip to content

Self-exploding tumor microenvironment-responsive nanomedicine as "ROS Bomb" ignites STING pathway for triple-negative breast cancer immunotherapy.

Aug 2026 · Journal of Controlled Release · pp. 115238 · 0 citations · 51 references
Medicine

TL;DR

It is reported that horseradish peroxidase (HRP) can catalyze artemisinin to generate ROS, and a "ROS bomb" nanomedicine was designed for antitumor immunotherapy, offering a potent approach for treating deep-seated tumors.

Abstract

Conventional reactive oxygen species (ROS)-mediated tumor therapies such as photo-, sono-, and chemodynamic therapies are often limited by inadequate penetration depth of external stimuli and insufficient endogenous ROS substrates (e.g., O₂ and H₂O₂). Here, we report that horseradish peroxidase (HRP) can catalyze artemisinin to generate ROS. Based on this, a "ROS bomb" nanomedicine was designed for antitumor immunotherapy. The nanocarrier consists of silica cross-linked micelles incorporating ROS-cleavable thioketal bonds and encapsulated artemisinin as the payload, with surface-immobilized HRP serving as the trigger. Within the tumor microenvironment with elevated H₂O₂, the thioketal linkers are cleaved to release artemisinin, initiating an HRP-catalyzed ROS cascade. The ROS burst induces immunogenic cell death and activates the STING pathway in dendritic cells assisted by the co-released drug SN38, effectively suppressing the growth of immunosuppressive triple-negative breast tumors. This exogenous ROS delivery strategy overcomes the restrictions of conventional ROS therapies, offering a potent approach for treating deep-seated tumors.

View source

Similar papers

Open access Aug 2026

Tumor microenvironment-remodeling cell membrane biomimetic nanoplatform for activated imaging and cascade-amplified treatment of breast cancer.

BIMLM is developed as a biomimetic nanoplatform integrating lactate oxidase (LOX)-driven lactate exhaustion with MnO2-coated IR-780 for TME remodeling and self-amplifying ROS generation that enhances PDT/CDT efficacy while triggering metabolic starvation and ferroptosis, which collectively enable tumor eradication.

Bo-Ye Zhang, Yu-Li Chen, Pengyan Qiao et al. · 0 citations
Sep 2026

Nanozyme-Driven Tumor Microenvironment Remodeling for Potentiated Phototherapy–Immunotherapy

A multifunctional manganese-based nanozyme loaded with indocyanine green (ICG) is developed to reprogram the immunosuppressive TME for potentiated phototherapy combined with immunotherapy and elicits robust immune memory to prevent recurrence and metastasis.

Chen-Lu Huang, Han-Yong Wang, Xin-Yu Yang et al. · 0 citations
Sep 2026

Enzyme-like bimetallic nanoclusters modulate tumor microenvironment to enhance radiosensitization for multimodal imaging and synergistic photothermal-radiotherapy.

This TME-responsive bimetallic nanoplatform successfully integrates radiosensitization, multimodal imaging, and PTT, offering a robust strategy for imaging-guided precision cancer therapy.

Rui-Ying Zhang, Miao-Qing Li, Rui Cao et al. · 0 citations
Aug 2026

A ROS-Responsive Photothermal Hydrogel for Tumor Microenvironment Reprogramming and STING-Mediated Immune Engagement.

This hydrogel-nanoparticle composite platform helps overcome photothermal therapy-induced immune suppression, reduce oxidative stress in the TME, and inhibit tumor metastasis, offering a promising strategy for enhancing cancer immunotherapy.

Jie Sun, Yun-Yun Wu, Sheng Zhao et al. · 0 citations
Sep 2026

Self-oxygenating nanoreactors enable effective low-dose X-ray photodynamic immunotherapy against refractory tumors.

A new type of self-oxygenating nanoreactor (HCCP) is engineered to relieve hypoxia and effectively eradicate radio-resistant triple-negative breast cancer (TNBC) by combining low-dose X-ray-induced photodynamic therapy (LX-PDT), cuproptosis and chemodynamic therapy (CDT), which was further discovered to trigger the sti...

Hong-Lian Yu, Jing Liu, Jun-Jie Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.